Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer Masaki ShiotaNaohiro FujimotoMasatoshi Eto Original Article 02 March 2020 Pages: 1155 - 1163
Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach Anat Globerson LevinNatalie KronikVladimir Vainstein Original Article 04 March 2020 Pages: 1165 - 1175
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort Abdul Rafeh NaqashBiagio RicciutiPaul R. Walker Original Article 05 March 2020 Pages: 1177 - 1187
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort Abdul Rafeh NaqashBiagio RicciutiPaul R. Walker Correction 28 April 2020 Pages: 1189 - 1189
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy Tali VoloshinNoa KaynanYoram Palti Original Article Open access 06 March 2020 Pages: 1191 - 1204
Adenosine-producing regulatory B cells in head and neck cancer Sandra S. JeskeMatthias BrandPatrick J. Schuler Original Article Open access 07 March 2020 Pages: 1205 - 1216
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo Anja Tatjana TeckSabrina UrbanSebastian Ochsenreither Original Article Open access 10 March 2020 Pages: 1217 - 1227
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer Ryota ShibakiShuji MurakamiYuichiro Ohe Original Article 10 March 2020 Pages: 1229 - 1236
Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets Diana Tronik-Le RouxMathilde SautreuilEdgardo D. Carosella Original Article 12 March 2020 Pages: 1237 - 1252
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes Asmaa M. ZahranHelal F. HettaOmnia El-Badawy Original Article 13 March 2020 Pages: 1253 - 1263
Tumor immune microenvironment in cancer patients with leukocytosis Kyung Hwan KimNam Suk SimYong Bae Kim Original Article 13 March 2020 Pages: 1265 - 1277
Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APCMin/+ mice Louis SzeponikPaulina AkeusMarianne Quiding-Järbrink Original Article Open access 17 March 2020 Pages: 1279 - 1292
Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis Guoshu BiZhencong ChenHong Fan Original Article 18 March 2020 Pages: 1293 - 1305
Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target Said FarschtschiLan KluweAndreas Kurtz Original Article Open access 19 March 2020 Pages: 1307 - 1313
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients Maya DadianiDaniela NeculaAdit Ben-Baruch Original Article 20 March 2020 Pages: 1315 - 1326
Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer Ruochen LiHeng ZhangJiejie Xu Original Article 21 March 2020 Pages: 1327 - 1336
In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies Edward PichinukMichael ChalikDaniel H. Wreschner Original Article 26 March 2020 Pages: 1337 - 1352
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas Martin F. OrthVeit Leonhard BueckleinThomas Knösel Original Article 28 March 2020 Pages: 1353 - 1362
Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas Christoph AroltMoritz MeyerJens Peter Klussmann Original Article Open access 30 March 2020 Pages: 1363 - 1373
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients Qian-Ting WangYing NieYou-Wen He Clinical Trial Report 20 February 2020 Pages: 1375 - 1387
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients Alessandra BattagliaAlexia BuzzonettiChristopher Nicodemus Correction 26 March 2020 Pages: 1389 - 1389